Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer

PCI in Cancer Patients: Adding Another Piece to a Complex and Still Very Incomplete Puzzle

“…First, the findings of the study by Campos et al, 3 together with previously available data, suggest that (1) patients with cancer should not be denied revascularization particularly in acute coronary syndrome presentations and that (2) shortened dual antiplatelet therapy duration (ie, 1 month) is probably a sound strategy in most of these patients, especially considering that even stent thrombosis rates, a particularly feared complication given its dismal prognosis, were low. This is especially important because available registry data from multiple countries has repeatedly shown that cancer patients are offered revascularization less often 4,9,10 and sometimes even lower-intensity medical therapy at discharge has been reported, even after ST-segment-elevation myocardial infarction. 10 Second, the current analysis suggests that decisions around antiplatelet therapy should be personalized.…”

“…This is especially important because available registry data from multiple countries has repeatedly shown that cancer patients are offered revascularization less often 4,9,10 and sometimes even lower-intensity medical therapy at discharge has been reported, even after ST-segment-elevation myocardial infarction. 10 Second, the current analysis suggests that decisions around antiplatelet therapy should be personalized. Calculation of the balance between ischemic risk/bleeding risk in this population with the ARC trade-off model identified that 19% of patients with cancer would have a greater risk of myocardial infarction/ST than BARC (Bleeding Academic Research Consortium) 3 to 5 bleeding highlighting that these patients may benefit from longer dual antiplatelet therapy duration.…”